Nanotechnology in Cancer Treatment Market Report 2025

The nanotechnology in the cancer treatment market size has grown rapidly in recent years. It will grow from $137.9 billion in 2024 to $159.09 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to the rising global prevalence of cancer, growing awareness of early cancer detection, increased research and development investments in nanomedicine, greater adoption of minimally invasive treatments, and expanded government funding for oncology nanotechnology research.

The nanotechnology in the cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $278.07 billion in 2029 at a compound annual growth rate (CAGR) of 15%. The growth in the forecast period can be attributed to the increasing demand for targeted cancer therapies, greater integration of nanotechnology in drug delivery systems, rising emphasis on personalized oncology treatments, a growing number of clinical trials for nano-enabled cancer drugs, and the expanding adoption of nanotheranostics in cancer care. Key trends expected during this period include advancements in nanoparticle-based drug delivery platforms, innovations in cancer-specific nanocarriers, the integration of AI with nanotechnology for precision oncology, the development of multifunctional nanodevices for both diagnosis and therapy, and the broader application of nanotheranostics in personalized medicine.

The rising demand for targeted therapies is expected to drive the growth of nanotechnology in the cancer treatment market in the coming years. Targeted therapies are cancer treatments that specifically address molecular markers or pathways involved in tumor growth and progression. Their growing popularity is due to their precision in attacking cancer cells, which reduces damage to healthy tissues and minimizes side effects. Nanotechnology enhances targeted therapies by enabling the precise delivery of drugs directly to cancer cells, improving treatment effectiveness while limiting harm to surrounding healthy tissues. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a U.S.-based professional membership organization, reported that the number of gene therapies in Phase II trials rose from 247 at the end of Q1 2023 to 260 at the end of Q2 2023, reflecting a 5% increase. Thus, the growing demand for targeted therapies is fueling the adoption of nanotechnology in cancer treatment.

Companies operating in the nanotechnology-based cancer treatment market are increasingly focusing on breakthroughs such as immunotherapy nano formulations to enhance immune system targeting while minimizing side effects for patients. Immunotherapy nano formulations use nanotechnology to deliver immune-based therapies directly to cancer sites, improving drug stability, bioavailability, and immune response activation. For instance, in December 2023, Cello Therapeutics, a U.S.-based biotechnology company, introduced CE120, a broad-spectrum therapeutic cancer nano vaccine that received clearance from the Food and Drug Administration. CE120 is the first clinical therapy to use platelet membrane-coated nanoparticles for the treatment of solid tumors. It combines targeted drug delivery with immune system activation, aiming to destroy tumors while preventing recurrence. This innovative platform strengthens both treatment precision and immune response, establishing CE120 as a pioneering nanomedicine in cancer therapy.

In March 2023, Sona Nanotech Inc., a Canada-based provider of nanotechnology for cancer treatments, acquired Siva Therapeutics for \$2 million. The acquisition supports Sona Nanotech’s expansion into cancer therapeutics by advancing gold nanorod-based targeted hyperthermia treatments for solid tumors, aligning with its mission to further develop nanotech-based cancer solutions. Siva Therapeutics Inc., based in the United States, specializes in nanotechnology-based cancer therapies, particularly through its targeted hyperthermia therapy (THT) platform.

Major players in the nanotechnology in cancer treatment market are Pfizer Inc., AstraZeneca PLC, Novartis AG, Amgen Inc., GE Healthcare Technologies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Arrowhead Pharmaceuticals Inc., Nanobiotix S.A., EnGeneIC Ltd., Nanospectra Biosciences Inc., Sona Nanotech Inc., CritiTech Inc., Immix Biopharma Inc., DNA Nanobots LLC, Nanovery Limited, CytImmune Sciences Inc., NanOlogy LLC, NanoApps Medical Inc., ARIZ Precision Medicine.

North America was the largest region in the nanotechnology in cancer treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nanotechnology in cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nanotechnology in cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Nanotechnology in cancer treatment involves the use of nanoscale materials and tools to improve cancer diagnosis, monitoring, and therapy. It enables precise drug delivery directly to cancer cells, minimizing damage to surrounding healthy tissues. This method is designed to enhance treatment effectiveness, reduce side effects, and advance personalized medicine approaches.

The primary types of nanotechnology used in cancer treatment include liposomes, dendrimers, and nanoparticles. Liposomes are small spherical vesicles composed of lipid bilayers that deliver drugs directly to targeted cells in the body. Treatment approaches include chemotherapy, immunotherapy, targeted therapy, combination therapies, and surgical assistance. These technologies are applied across different cancer types, including breast cancer, lung cancer, prostate cancer, colorectal cancer, blood cancer, and others. Key applications include targeted drug delivery, photothermal therapy, radiation therapy enhancement, diagnostics and imaging, and gene delivery systems. End-users of these technologies include hospitals, research institutions, diagnostic laboratories, pharmaceutical companies, and contract research organizations (CROs).

The nanotechnology in cancer treatment market research report is one of a series of new reports that provides nanotechnology in cancer treatment market statistics, including the nanotechnology in cancer treatment industry global market size, regional shares, competitors with the nanotechnology in cancer treatment market share, detailed nanotechnology in cancer treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the nanotechnology in cancer treatment industry. This nanotechnology in cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nanotechnology in cancer treatment market consists of revenues earned by entities by providing services such as hyperthermia therapy services, multi-drug co-delivery services, and immune checkpoint modulation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nanotechnology in cancer treatment market also includes sales of magnetic nanoparticles, carbon nanotubes, polymeric nanoparticles, and quantum dots. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.